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Mastectomy (MAST) has progressively been repla-
ced by more conservative approaches. There is enou-
gh evidence obtained in randomized controlled 
trials to suggest to patients to choose for a CBS, pro-
vided the tumor diameter allows an acceptable cos-
metic result after curative surgery. Quadrantectomy 
(QUAD) tested in the Milan trials is an alternative 
surgical approach to MAST resulting in excellent 
local control.1 Tumorectomy has been proposed as 
an alternative to QUAD. Provided external adjuvant 
radiation therapy is offered to patients submitted to 
less than MAST, the long term local control rates 
are similar to more radical surgical approaches and 
the cosmetic results are considered good to excel-
lent both by physicians and patients. Interestingly, 
in the Milan experience the local recurrence rate in 
the group of patients submitted to QUAD, axillary 
dissection without adjuvant radiotherapy is similar 
to the rate observed in the subgroup of patients trea-
ted with TUM, axillary dissection and radiothera-
py. One could potentially conclude from these data 
that a more radical surgery such as QUAD gives 
the opportunity to avoid radiotherapy in node ne-
gative patients. However, the best local control rate 
is observed after QUAD, axillary dissection and ra-
diotherapy with a recurrence rate not exceeding the 
one observed after MAST. This difference between 
TUM and QUAD is especially evident for patients 
with an extensive intraductal component (EIC). 
One explanation may be related to the amount of 
residual disease after TUM especially in case of an 
EIC, which in the Milan trials was not eliminated 
by the adjuvant radiotherapy.2,3 Based on these data, 
one could consider there is an optimal margin after 
resection of the primary tumor. If this margin is ob-
tained, residual tumor burden is probably that low 
that an optimal effect of adjuvant radiotherapy can 
be expected. The incidence of residual carcinoma 
depends on margin status as illustrated in Table 1.
Definition of a tumor-free margin
It is difficult to compare the published data for se-
veral reasons. The very first question is obviously 
how to adequately define the resection margin. One 
should not forget that the assessment of the mar-
gin status is a sampling procedure prone to error. 
It has been shown that at least more than 3,000 
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histological sections would be required to fully exa-
mine the surface of a spherical specimen only 2cm 
in diameter.4 On the other hand, the interpretation 
of the data on margins is particularly hazardous as 
local and distant failure are very often considered 
as independent events during the statistical inter-
pretation of clinical data. Hence censoring patients 
with distant metastases when analysing local con-
trol may heavily bias the results. Therefore, one can 
assume that the reported incidence of local recur-
rence in most published data is extremely variable 
and is only an underestimate of the true recurrence 
rate (Table 2). A methodology based on competing 
risks is therefore more appropriate. Using this sta-
tistical approach patients developing distant me-
tastases are not censored but considered as success 
provided there is no indication for a local recur-
rence. Moreover, as shown in the overview by Sin-
gletary et al, the adverse effect of positive margins 
on local recurrence (LR) is influenced significantly 
by follow-up duration (Table 2). In case of nega-
tive margins there is no significant change in LR 
rates at follow-up times ranging from 36 to 120 
(r = -0.31, p = NS) months whereas in case of po-
sitive margins, the LR rates increases significantly 
(r = 0.75, p = 0.008).5
Moreover, there are various techniques described 
for margin assessment such as frozen section analy-
sis and touch preparation analysis. One should not 
only estimate whether the resection margin is posi-
tive or “close”, but also try to estimate quantitatively 
the extent of positive margins.2,6 It seems important 
to define not only the clearance around the tumor 
in mm but also the number of positive margins 
(Table 3).6 There is currently no consensus in the 
literature on the definition of a “close” and negative 
margin.5,7 There is a remarkable difference between 
North America (US) and Europe (EU): nearly 50% 
of health care professionals involved in breast cancer 
treatment are considering that the absence of cells 
at the inked margin can be considered as a nega-
tive margin in the US, whereas in the EU we are 
mostly considering a negative margin when there 
is a minimal clearance of 2mm.7 This is obviously 
not without consequences on the burden of residual 
tumor potentially left after CBS (Table 1). It is parti-
cularly difficult to compare the efficacy of radiation 
therapy in this context. In most of the randomized 
trials, selected in the nineties to define the Natio-
nal Institute of Health (NIH) consensus statement, 
there’s an enormous variability in the definition of a 
negative margin (Table 4).7 Consequently this yields 
a wide variation of guidelines and treatment poli-
cies in different institutions. Some are considering 
that the absence of tumor cells at the inked margin 
as defined in the NSABP trials is adequate whereas 
others require a margin of at least 1 to 3cm.7-9 The 
former state that local control can be obtained with 
a more aggressive post-CBS approach, whereas the 
latter claim that close or positive margins predispose 
to ipsi-lateral breast tumor recurrence leading to a 
reduction of disease free and overall survival (Table 3).10
Prognostic factors in case of close margins
Close margins do not always have the same prog-
nostic value. Holland et al have described the re-
sidual tumor cell burden as a function of the dis-
tance in millimetres from the resection margin to 
the primary tumor.11,12 Not all histological sub-
types of breast cancer carry the same risk. It has 
clearly been demonstrated that infiltrating lobular 
carcinoma (ILC) is much more prone to harbour 
positive margins than infiltrating ductal carcino-
ma (IDC). This is easily explained by the typical 
infiltration pattern of ILC. The incidence of posi-
tive margins for ILC ranges from ± 20% to ± 50% 
(Table 5).13-17
The type of tumor is not the only factor leading to 
an increased risk of a positive margin. The negative 
impact of an EIC was illustrated in the Milan trial. 
In the work of Holland et al the incidence of residual 
cells at a distance of ≥ 2cm and ≥ 4cm highly de-
pends on the presence of an EIC in the pathological 
Table 1. residual carcinoma after CBS depends on margin status (Modified from Wazer et al.)2,3
Margin assessment Residual carcinoma
Tumor at inked margin 46 – 67 %
Margins “close” to the tumor 23 – 32 %
Margins negative 12 – 26 %
Presence of an EIC 31 – 88 %
EIC = extensive intra-ductal component.
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specimen (Table 6 ).11,12
It has been reported several times that age is pre-
dicting a worse outcome in breast cancer.18-22  The 
question is why do young patients fail? Wazer et al 
highlight several reasons; one of these reasons is the 
presence of an EIC which is known to be associa-
ted with an increased risk of positive or close mar-
gins.21 Together with other factors such as a poor 
histological grade, presence of lympho-vascular in-
vasion, multi-centricity, negative oestrogen receptor 
status, presence of necrosis, the risk of recurrence 
is increased as compared to an older patient popu-
lation. The same author demonstrates a near linear 
relationship between risk of tumor residuum and 
Table 2: Impact of positive (2a) or close (2b) margins on local recurrence rate (LRR). The first 
column relates to the definition of the margin as published. The data are tabulated according 
to the definition of the margin and are given in median and ranges. N relates to the number of 
studies. The last three lines of Table 2a relate to studies with a follow-up exceeding 100 months 
(numbers in bold) (Modified from Singletary E).5
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margin status but the risk is considerably higher in 
patients younger than 45 years.21 However, in this 
same cohort of patients the risk of residual tumor 
becomes independent of age and tumor margin in 
case of EIC. This latter observation clearly illustrates 
the complex relationship between tumor- and host-
related factors, and the necessity to rely on large pa-
tient cohort data to make any meaningful conclu-
sion on independent prognostic and predictive value 
of these various factors.  
Does more intensive treatment solve the 
problem?
On can argue that tumor margin does not really 
matter provided no cells are found at the resection 
margin. The argument holds true if one can pro-
pose a tailored treatment to annihilate the risk of 
residual tumor after CBS. The philosophy behind 
this approach is easily understandable as one aims 
to obtain the best cosmetic result in case of CBS.9 
However, is there any published evidence around 
to claim that a more aggressive local postoperative 
treatment is able to control the disease without 
hampering cosmetic outcome later on? 
Boosting the tumor bed is traditionally used in 
radiotherapy after CBS.23 This approach is based 
on evidence issued from randomized trials. In the 
EORTC trial, the amplitude of the impact of the 
boost is age dependent.24 Although one cannot dis-
tinguish a patient population which does not bene-
fit from the boost, the therapeutic efficacy is larger 
in younger patients. Does that mean that the boost 
dose is sufficient to compensate in case of close mar-
gins? There is no real evidence in the current litera-
ture to support such a statement. On the contrary, 
there are data available showing that even a boost-
dose tailored to the margin extent does not compen-
sate for the increased risk of local recurrence. Leong 
et al for example, have increased the boost dose in 
function of the margin extent, raising the total dose 
up to 81Gy.19 Notwithstanding this rather high total 
dose, the local recurrence rate remains unaccepta-
ble especially in younger patients (< 35 years). The 
ipsilateral breast tumor recurrence (IBTR) is 50%, 
33% and 20% in case of positive, indeterminate 
and negative margins respectively. Similar data have 
been published by Neuschatz et al.25 The boost dose 
after a 50 Gy whole breast irradiation in their series 
varies from 0 Gy in case of negative margins to 20 
Gy if a positive margin is described after CBS. In 
between, the boost dose is tailored to the clearance 
in mm. Again, the incremental dose is not able to 
completely eliminate the risk of an IBTR. The 12 
Table 3. Local control (LC) at 5 and 10 years as a function of number of positive margins. It is 
noteworthy that in this set of patients there is no difference in LC between patients with an R0 
resection and patients with a single positive margin (Modified from DiBiase et al).6
5-years local control 10-years local control
1 positive margin 91% 74%
> 1 positive margin 77% 63%
Table 4. Definition of tumor margin in randomized controlled trials (used for the NIH consensus 
statement) (Modified from Taghian et al).7
Trial Years Margin definition
NSABP 1976 – 1984 No tumor cells at inked margin
NCI 1979 – 1987 No margin requirements
EORTC 1980 – 1986 Requiring a macroscopic margin of 1cm
DBCSG 1983 – 1989 Requiring < R2 resection (R0 and R1 eligible)
IGR 1972 -1980 Requiring a 2 cm margin
Milan 1973 - 1980 QUAD with 2-3 cm margin
NSABP: National Surgical Adjuvant Breast and Bowel Project; NCI: National Cancer institute; EORTC: European Or-
ganization for Research and Treatment of Cancer; DBCSG: Danish Breast Cancer Study Group; IGR: Institut Gustave 
Roussy. 
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year actuarial local failure after a 20 Gy boost is 
still 17% in case of a positive margin. In contrast, 
the corresponding number after a 10 Gy boost dose 
is 0% in case of a clearance exceeding 5mm. For a 
clearance larger than 0 and up to 2 millimetres the 
local failure rate is still 9% after a boost dose of 20 
Gy. One should realize that in most radiotherapy 
departments, based on the data from the EORTC 
and the Lyon-trial, the boost dose generally does not 
exceed 16Gy.23,26
Moreover, in the context of a revival of hypo-fracti-
onation, a treatment schedule often used to reduce 
the treatment burden on the patients and to save 
machine time in busy departments, the role of the 
boost dose has still to be redefined making the esti-
mation of the exact risk of an IBTR in case of close 
margins even more problematic.27
Partial breast irradiation instead of whole breast 
followed by a boost is currently under investiga-
tion.28 The approach potentially allows the concep-
tion of a margin dependent intensive dose escala- 
tion. However, this approach is still to be consid-
ered experimental and must be tested in well de-
signed randomized trials with an extensive quality 
control for the analysis of the pathological spe-
cimen and the assessment of the margin extent. 
Long-term data are mandatory to assess impact on 
cosmetic outcome. Moreover, experimental mo-
dels vlearly illustrate that in case of breast cancer, 
the stem cells, known to be more resistant to tre-
atment, are located at the periphery of the tumor 
exactly with-in the region potentially left behind 
after limited surgery. The latter may not be ade-
quately covered when using certain surgical and 
radiation therapy techniques as the one suggested 
by authors using partial breast irradiation.
One should also realize that breast remodelling 
often performed during CBS greatly complicates 
the definition of the target volume at risk for the 
boost dose. There are two ways to deal with this 
problem: the first one is to cover larger volumes but 
this harbours the risk of increased long term toxi-
city and a worse cosmetic outcome, the second one 
is leaving the cavity as it is but this again might be 
deleterious for the final cosmetic aspect. Anyway, 
we strongly suggest surgeons to clip the surgical 
tumor bed but even that can be misleading for the 
definition of the target volume for the boost especi-
ally when breast remodelling has been performed.
One can argue that for patients requiring a syste-
mic treatment, the local recurrence risk will be re-
duced adequately if patients are submitted to adju-
vant chemotherapy. There are no randomized trials 
available which are sufficiently powered to defini-
tely settle the question about the optimal sequence 
when chemotherapy and radiotherapy have to be 
combined in the adjuvant setting.29,30 The conco-
mitant use of doxorubicin-based regimens and ra-
diotherapy is not feasible regarding the potentially 
powerful interactions and hence toxicity. Delaying 
local adjuvant radiotherapy after systemic therapy 
may therefore harbour an intrinsic risk of an incre-
Table 5. Different rates of positive margin (in %) can be explained by tumor histology i.e. infiltra-
ting lobular carcinoma (ILC) versus infiltrating ductal carcinoma (IDC).
Author / reference ILC IDC p
Mai et al 13 52% 26% NR
Moore et al 14 51% 15% < 0.05
Silverstein et al 15 59% 43% < 0.003
White et al 17 63% 60% NS
Yeatman et al 16 17.5% 6.9% 0.018
NR: not reported; NS: not significant.
Table 6. Residual carcinoma at a distance of 2 and 4 cm depends on the presence of an extensive 
intraductal component (EIC) (Modified from Holland et al).11,12
EIC Positive Negative
Residual tumor at > 2cm 59% 29%
Residual tumor at > 4cm 32% 12%
v o l .  3  i s s u e  3  -  2 0 0 9  B E L G I A N  J O U R N A L  O F  M E D I C A L  O N C O L O G Y
R E V I E W  O N C O L O G Y
98
ased local recurrence, especially in case the resec-
tion margin is “close” to the tumor. Therefore, one 
should be cautious with these particular patients 
and Bellon et al states that obtaining “clear” mar-
gins by re-excision seems prudent before starting 
chemotherapy.29 In a randomized trials publish-
ed by Recht et al, the importance of the status of 
the tumor margin is highlighted. If the margin is 
close, positive or unknown, the incidence of local 
recurrence is higher in the chemotherapy first arm 
(CMF-P regimen) and the higher incidence of dis-
tant metastases in the radiotherapy-first arm group 
persists.30 In the era of anthracycline-based chemo-
therapy, an abstract by Bellon et al reports a local 
recurrence rate of 32% in the chemotherapy-first 
arm as compared to 4% in the radiotherapy-first 
arm in their updated results of a randomized trial 
designed to evaluate the impact of the sequence in 
the adjuvant setting.31
The evidence concerning the possibility to reduce 
the risk by increasing the intensity of the adjuvant 
approach is not yet available. In the retrospective 
analysis of prospective randomized controlled tri-
als runned by the Cancer and Leukemia Group B 
(CALGB 9344), Sartor et al claim that adding pacli-
taxel to doxorubicin and cyclophosphamide in node 
positive breast cancer patients, further reduces the 
risk of loco-regional recurrence at 5 years despite the 
further delay in the initiation of radiotherapy post-
lumpectomy or in selected cases after mastectomy.32 
This author also states that margin status clearly in-
fluences the risk of local recurrence but quantitative 
data on how close the margins were are not available.
Conclusions
Being as conservative as possible is certainly a “lau-
dable” approach especially - but not only - in young 
patients. However, this philosophy should not pre-
dominate over the risk of a local recurrence which 
yields demonstrable survival deficits. One should be 
aware that, especially in young patients and in case 
of EIC, radiotherapy is not able to reduce the risk of 
local recurrence to reasonably acceptable numbers. 
Increasing the dose to higher levels, does not really 
seem to help in tackling the local problem. Increas-
ing the intensity of the adjuvant chemotherapy does 
improve local control but harbours the risk of delay-
ing radiotherapy in patients, especially in those at 
risk of a local recurrence. One should therefore be 
particularly cautious with close margins and evalu-
ate the possibility of a surgical re-intervention, even-
tually consider mastectomy and reconstruction, es-
pecially in young patients and patients with an EIC.
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